Disease · MONDO_0005515

oral cavity cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. oral cavity cancer. Diseases, record MONDO_0005515. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005515

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: oral cavity cancer; Open Targets
Open Targets ID: MONDO_0005515; Open Targets
Other names: cancer of oral cavity, malignant mouth neoplasm, malignant mouth tumor, malignant mouth tumour, malignant neoplasm of mouth, malignant neoplasm of oral cavity, malignant neoplasm of the mouth, malignant oral cavity neoplasm, malignant oral cavity tumor, malignant oral cavity tumour, malignant tumor of anterior floor of mouth, malignant tumor of lateral floor of mouth, malignant tumor of mouth, malignant tumor of oral cavity, malignant tumor of the mouth, malignant tumour of anterior floor of mouth, malignant tumour of lateral floor of mouth, malignant tumour of mouth, malignant tumour of oral cavity, malignant tumour of the mouth; Open Targets
Disease Ontology: DOID:8618; Disease Ontology
NCI Thesaurus: C9314; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 5 of its 21 drugs, from ClinicalTrials.gov; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets85

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1956	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/7915	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/1642	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2064	Drugs and targets

1 to 10 of 85

See all 85 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02827838	Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer	Early phase 1	17	2025-03-17	Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma	DURVALUMAB	Its record names the disease	ClinicalTrials.gov
NCT03021993	Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer	Phase 2	17	2025-11-12	Oral Cavity SCC	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02917629	ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment	Phase 2	6	2023-03-08	Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7	METFORMIN HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01525927	Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity	Phase 2	2	2015-09-30	Oropharyngeal Neoplasms	CARBOPLATIN, CISPLATIN, DOCETAXEL, FLUOROURACIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00934739	A Study of High-Risk Oral Cavity Cancer	Phase 2/3	150		Oral Cavity Cancer	CELECOXIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT05893888	A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers	Phase 2/3	40		Oral Squamous Cell Carcinoma	CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03357757	Avelumab With Valproic Acid in Virus-associated Cancer	Phase 2	39		Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona	AVELUMAB, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01760811	CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT	Phase 1/2	25		Squamous Cell Carcinoma	CETUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06219980	SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx	Phase 2	25		SBRT	CISPLATIN, DOCETAXEL	Its record names the disease	ClinicalTrials.gov
NCT00203905	A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck	Phase 2	23		Head and Neck Cancer	BEVACIZUMAB, FLUOROURACIL, HYDROXYUREA	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment (Durvalumab, Surgery) - HPV Negative vs Treatment (Durvalumab, Surgery) - HPV Positive: deaths from any cause	1 of 11	0 of 6	17	NCT02827838	Trial comparisons
Treatment (Durvalumab, Surgery) - HPV Negative vs Treatment (Durvalumab, Surgery) - HPV Positive: serious adverse events	5 of 11	0 of 6	17	NCT02827838	Trial comparisons
Group I (ACTOplus Met XR) vs Group II (Placebo): deaths from any cause	0 of 4	0 of 2	6	NCT02917629	Trial comparisons
Group I (ACTOplus Met XR) vs Group II (Placebo): serious adverse events	0 of 4	0 of 2	6	NCT02917629	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34755137	DERIVED	1	PubMed
34755131	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005515

GET https://conductscience.org/api/diseases/v1/MONDO_0005515/drugs?page=2

API reference For AI assistants